Capecitabine breast cancer study

Adjuvant Capecitabine for Breast Cancer after Preoperative ...

★ ★ ★ ☆ ☆

Original Article from The New England Journal of Medicine — Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy ... Buzdar AU, et al. Multicenter phase II study of ...

Adjuvant Capecitabine for Breast Cancer after Preoperative ...

Capecitabine (Xeloda) to Treat Breast Cancer | News

★ ★ ★ ★ ★

The median progression-free survival for breast cancer patients treated with the standard dosage of capecitabine is 4.3 months, as reported in the study “Efficacy of Very-Low-Dose Capecitabine in Metastatic Breast Cancer.” Treatment with capecitabine can cause side effects.

Capecitabine (Xeloda) to Treat Breast Cancer | News

Multicenter phase II study of oral capecitabine (Xeloda ...

★ ★ ★ ★ ★

3/14/2012 · An additional phase III study of first-line capecitabine in MBC patients is the randomized PEgylated LIposomal doxorubicin versus CApecitabiNe as first-line chemotherapy for metastatic breast cancer (PELICAN) study, which compared the efficacy of capecitabine (1,250 mg/m 2 bid, days 1–14, every 21 days) with that of pegylated liposomal doxorubicin (PLD) dosed at 50 mg/m 2 every 28 days …

Multicenter phase II study of oral capecitabine (Xeloda ...

Capecitabine - National Cancer Institute

★ ★ ★ ★ ☆

A drug called Xeloda can extend the lives of some women whose breast cancer is not wiped out by standard treatment, a new clinical trial finds. Oncologists said the results are "practice-changing ...

Capecitabine - National Cancer Institute

Capecitabine Monotherapy: Review of Studies in First-Line ...

★ ★ ★ ☆ ☆

A Japanese study has found that women diagnosed with early-stage, HER2-negative breast cancer with residual disease who were treated with Xeloda after surgery had better survival compared to women who didn’t get chemotherapy after surgery. The study was presented on Dec. 9, 2015 at the 2015 San Antonio Breast Cancer Symposium.

Capecitabine Monotherapy: Review of Studies in First-Line ...

"Landmark" study shows breast cancer drug Xeloda can ...

★ ★ ☆ ☆ ☆

patients with gastrointestinal cancer. 5-7 However, its efficacy in patients with breast cancer is un-clear.8,9 Capecitabine has been shown to be effec-tive in patients with metastatic breast ...

Treating Residual Disease With Xeloda Improves Survival in ...

★ ★ ☆ ☆ ☆

11/25/2013 · Our objective was to investigate the efficacy and safety of capecitabine maintenance therapy (CMT) after capecitabine-based combination chemotherapy in patients with metastatic breast cancer. The clinical data of 139 metastatic breast cancer …

Treating Residual Disease With Xeloda Improves Survival in ...

Adjuvant Capecitabine for Breast Cancer after Preoperative ...

★ ★ ☆ ☆ ☆

Standard Versus Continuous Capecitabine in Advanced Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

Adjuvant Capecitabine for Breast Cancer after Preoperative ...

Capecitabine maintenance therapy in patients with ...

★ ★ ★ ★ ☆

Typically it's used to treat metastatic breast cancer that has stopped responding to Taxol, Taxotere, and Adriamycin. How it's given: Xeloda is taken orally as a pill. Additional information: Xeloda is in an inactive form when you take it. Your liver, and then enzymes in the cancer cells, convert it to its active cancer-fighting form, 5 ...

Capecitabine maintenance therapy in patients with ...

Standard Versus Continuous Capecitabine in Advanced Breast ...

★ ★ ★ ☆ ☆

12/9/2015 · SAN ANTONIO — Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast ...

Standard Versus Continuous Capecitabine in Advanced Breast ...

Xeloda - breastcancer.org

★ ★ ☆ ☆ ☆

4/1/2013 · Abstract. Purpose: Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis.

Xeloda - breastcancer.org

Capecitabine Improved Outcomes for Breast Cancer Patients ...

★ ★ ★ ★ ☆

4/1/2006 · Cancer and Leukemia Group B (CALGB) study 49907: Adjuvant treatment for breast cancer. CALGB study 49907 is a randomized, open-label, multicenter, phase III trial investigating adjuvant chemotherapy (postoperative) in women ≥65 years of age with local or regional breast cancer.

Capecitabine Improved Outcomes for Breast Cancer Patients ...

Dasatinib plus Capecitabine for Advanced Breast Cancer ...

★ ★ ★ ★ ★

11/25/2015 · A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

Dasatinib plus Capecitabine for Advanced Breast Cancer ...

Capecitabine Monotherapy: Safe and Effective Treatment for ...

★ ★ ★ ☆ ☆

The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill ...

Capecitabine Monotherapy: Safe and Effective Treatment for ...

A Study of Tucatinib vs. Placebo in Combination With ...

★ ★ ★ ☆ ☆

Final results from the CREATE-X trial show capecitabine (Xeloda) could lower the risk of new breast cancer, recurrence or death by 30 percent or more. The randomized, phase III trial showed the most benefit in people with triple-negative breast cancer. Some oncologists have called the study “practice-changing.” LBBC first reported on early data from this trial in 2015.Background

A Study of Tucatinib vs. Placebo in Combination With ...

Clinical Trials Using Capecitabine - National Cancer Institute

★ ★ ★ ☆ ☆

2/20/2019 · Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities. We conducted a phase 1b/2 study …

Clinical Trials Using Capecitabine - National Cancer Institute

Capecitabine Could Greatly Lower Risk of New Breast Cancer ...

★ ★ ★ ★ ★

Introduction. The purpose of this study was to evaluate the safety and efficacy of ixabepilone plus capecitabine in patients with metastatic or locally advanced triple-negative breast cancer (TNBC).

Capecitabine Could Greatly Lower Risk of New Breast Cancer ...

A phase 1b/2, open-label, dose-escalation, and dose ...

★ ★ ★ ★ ☆

This study was an open-label phase 1b study with dose-escalation and expansion cohortsin advanced HER2-positive progressive metastatic breast cancer, done in five hospitals in the USA. In the dose-escalation phase, a modified 3 + 3 dose- ... capecitabine. : breast cancer. ...

A phase 1b/2, open-label, dose-escalation, and dose ...

Efficacy and Safety of Ixabepilone and Capecitabine in ...

★ ★ ★ ☆ ☆

Six trials were conducted in the adjuvant setting and two in the neoadjuvant setting. Capecitabine was added to standard chemotherapy in six studies and used in place of standard treatment in two. Four trials reported subgroup analysis according to breast cancer subtypes. The study characteristics are summarised in Table 1.

Efficacy and Safety of Ixabepilone and Capecitabine in ...

Tucatinib with capecitabine and trastuzumab in advanced ...

★ ★ ★ ★ ★

5/24/2018 · Tucatinib in combination with capecitabine and trastuzumab had acceptable toxicity and showed preliminary anti-tumour activity. Validation of the current study results will be determined in the double-blinded randomised study, HER2CLIMB (ONT-380-206; NCT02614794).

Tucatinib with capecitabine and trastuzumab in advanced ...

Capecitabine in early breast cancer: A meta-analysis of ...

★ ★ ★ ★ ☆

A study of adjuvant capecitabine in triple-negative breast cancer was largely negative, but disease-free and overall survival were improved in a subset of patients with the nonbasal-like phenotype.

Capecitabine in early breast cancer: A meta-analysis of ...

Tucatinib with capecitabine and trastuzumab in advanced ...

★ ★ ★ ☆ ☆

This phase II study evaluated the safety and efficacy of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Thirty-nine patients with metastatic breast cancer received 30 mg/m2 of docetaxel on days 1, 8, and 15 in

Tucatinib with capecitabine and trastuzumab in advanced ...

TNBC Study of Capecitabine Mostly Disappoints, With One ...

★ ★ ★ ★ ★

10/2/2002 · This supplement to ONCOLOGY includes a collection of papers focusing on the clinical development and use of capecitabine (Xeloda), a novel agent with significant activity in patients suffering from metastatic breast cancer. It is now clear that this

TNBC Study of Capecitabine Mostly Disappoints, With One ...

Phase II Study of Weekly Docetaxel and Capecitabine in ...

★ ★ ★ ☆ ☆

Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and ...

Phase II Study of Weekly Docetaxel and Capecitabine in ...

Capecitabine in the Treatment of Advanced Breast Cancer ...

★ ★ ☆ ☆ ☆

2/23/2010 · Study design. This was a single-arm open-label expanded access study of lapatinib in combination with capecitabine for male and female patients …

Capecitabine in the Treatment of Advanced Breast Cancer ...

Adjuvant Capecitabine Improves Survival in HER2-Negative ...

★ ★ ★ ★ ★

Purpose: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate. This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m 2 /d given for 2 weeks followed by a 1 -week rest period and repeated in 3-week cycles, in patients with paclitaxel-refractory metastatic breast cancer.

Adjuvant Capecitabine Improves Survival in HER2-Negative ...

Treatment of HER2-positive metastatic breast cancer with ...

★ ★ ★ ☆ ☆

1/1/2005 · Breast cancer is the most common malignancy in women in Western countries and is the most frequent cause of cancer mortality in this population. Furthermore, older women have a higher risk of developing breast cancer, and the majority of patients with breast cancer are older than 65 years.

Treatment of HER2-positive metastatic breast cancer with ...

Multicenter phase II study of capecitabine in paclitaxel ...

★ ★ ★ ★ ☆

Phase III study of adjuvant capecitabine in patients with HER2-negative breast cancer and pathologic residual disease following standard anthracycline/taxane neoadjuvant chemotherapy.

Multicenter phase II study of capecitabine in paclitaxel ...

Phase I/II study of capecitabine and vinorelbine in ...

★ ★ ☆ ☆ ☆

Abstract. Objective: Capecitabine is an antimetabolic fluoropyrimidine deoxynucleoside carbamate drug that can be converted to 5-FU in vivo.Currently, the role of capecitabine in the treatment of advanced breast cancer has been recognized. Also, Several meta-analyses have elucidated the role of capecitabine in the treatment of breast cancer, indicating that taxane-based regimen with ...

Phase I/II study of capecitabine and vinorelbine in ...

CREATE-X: Capecitabine in HER2- EBC - Breast Cancer - 2015 ...

★ ★ ★ ★ ★

10/2/2002 · ABSTRACT: A recent phase III trial demonstrated that the combination of capecitabine (Xeloda) and docetaxel (Taxotere) significantly improved objective tumor response rate, time to disease progression, and overall survival compared with single-agent docetaxel in anthracycline pretreated patients with advanced breast cancer.

CREATE-X: Capecitabine in HER2- EBC - Breast Cancer - 2015 ...

Addition of Capecitabine in Breast Cancer First-line ...

★ ★ ★ ★ ☆

The study nurses said it was a practical system and they felt confident that peoples’ side effects were managed quickly; The study team concluded that it is possible to use a mobile phone application to check on treatment side effects. And to change people’s capecitabine dose so they can have the best dose possible to treat their cancer.

Addition of Capecitabine in Breast Cancer First-line ...

Capecitabine and Docetaxel in Advanced Breast Cancer ...

★ ★ ★ ★ ☆

Dasatinib Plus Capecitabine for Advanced Breast Cancer ...

Capecitabine and Docetaxel in Advanced Breast Cancer ...

A study looking at capecitabine chemotherapy doses in ...

★ ★ ★ ★ ★

12/5/2018 · Adjuvant capecitabine provided no survival benefit for patients with early triple-negative breast cancer, except for those with nonbasal-like disease. The following article features coverage from ...

A study looking at capecitabine chemotherapy doses in ...
Known-bible-study-curriculum.html,Koko-monkey-study.html,Konvergen-divergent-fisika-study.html,Korean-study-company.html,Korean-unit-study.html